

1230 US Highway 11 Gouverneur, NY 13642 Phone: 1-877-635-9545

Prior Authorization Fax: 1-844-712-8129

Actemra[®] Prior Authorization Request Form (Page 1 of 2)

Member Information (required)			Provider Information (required)			
Member Name:			Provider Name:			
Insurance ID#:			NPI#:		Specialty:	
Date of Birth:			Office Phone:			
Street Address:			Office Fax:			
City:	State:	Zip:	Office Street Address:			
Phone:			City:		State:	Zip:
Medication Information (required)						
Medication Name:			Strength:	lirea)	Do	sage Form:
Check if requesting brand			Directions for Use:			
Check if request is for continuation of therapy						
Clinical Information (required)						
Select the diagnosis below: Active polyarticular juvenile idiopathic arthritis (PJIA) – For intravenous administration only Active systemic juvenile idiopathic arthritis (SJIA) – For intravenous administration only Giant cell arteritis Moderately to severely active rheumatoid arthritis (RA) Other diagnosis:						
Other diagnosis:ICD-10 Code(s):						
Clinical Information: Is Actemra prescribed by or in consultation with a rheumatologist? Will the patient use Actemra in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]? Yes No						
For active polyarticular juvenile idiopathic arthritis (PJIA), also answer the following:						
Does the patient have history of failure, contraindication, or intolerance to one of the following non-biologic disease modifying anti- rheumatic drugs (DMARDs): Arava (leflunomide) OR Rheumatrex/Trexall (methotrexate)? D Yes D No						
For active systemic juvenile idiopathic arthritis (SJIA), also answer the following:						
Does the patient have history of failure, contraindication, or intolerance to one non-steroidal anti-inflammatory drug (NSAID) [e.g., Motrin (ibuprofen), Naprosyn (naproxen)]?						
Does the patient have history of failure, contraindication, or intolerance to systemic glucocorticoid (e.g., prednisone)? 🗆 Yes 🗅 No						
For giant cell arteritis, also answer the following: Has the patient had trial and failure, contraindication, or intolerance to glucocorticoid (i.e., prednisone)? U Yes U No						
For moderately to severely active rheumatoid arthritis (RA), also answer the following:						
Does the patient have history of failure, contraindication, or intolerance to one non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., Rheumatrex/Trexall (methotrexate), Arava (leflunomide), Azulfidine (sulfasalazine)]?						
Select if the patient has history of failure, contraindication, or intolerance to the following: Cimzia (certolizumab) Humira (adalimumab) Simponi (golimumab) or Simponi Aria (golimumab IV) Is this request for continuation of prior Actemra therapy? Yes No						
Reauthorization:						
If this is a reauthorization request, answer the following questions:						
Is there documentation the patient has had a positive clinical response to Actemra therapy? Yes No						
Will the patient use Actemra in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]?						
This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of ProAct. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in						

this document is against the law. **If you are not the intended recipient, please notify the sender immediately.** Office use only: Actemra_January_2018



Date:

Actemra[®] Prior Authorization Request Form (Page 2 of 2)

 Quantity Limit Requests:

 What is the quantity requested per MONTH? ________

 What is the reason for exceeding the plan limitations?

 □ Titration or loading dose purposes

 □ Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)

 □ Requested strength/dose is not commercially available

 □ Other:

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician fe els is important to this review?

Please note:

This request may be denied unless all required information is received.

Please fax this form to 1-844-712-8129 to initiate a prior authorization review for the member and medication above. Please note: plan benefits may limit or exclude coverage of specific medications including those requested on this form.

I certify, to the best of my knowledge, the statements and information provided on this form are factual and correct.

Provider/Representative (and Title):

 PROACT INTERNAL USE ONLY:

 Clinical view Decision

 Approved, through

 Denied (documentation attached, if necessary)

 Tracking:

 1st Attempt
 2nd Attempt
 Letter Mailed:
 Letter Mailed:

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of ProAct. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.** Office use only: Actemra_January_2018